Previous studies have primarily focused on CK18 as a biomarker of steatohepatitis (NASH/MASH) and fibrosis progression [13, 14], but its potential association with cardiovascular involvement in NAFLD remains largely unexplored. Here, KRT18 is linked to metabolic dysfunction-associated steatotic liver disease.